German society for combating lipid metabolism disorders and their secondary diseases

from Wikipedia, the free encyclopedia

The German Society for Combating Lipid Metabolism Disorders and their Consequential Diseases DGFF (Lipid League) eV is a registered non-profit association founded in 1988 . The chairman is (as of 2018) the cardiologist Oliver Weingärtner , senior physician at the Clinic for Internal Medicine I at the Jena University Hospital.

The company has set itself the task of informing the German population and medical profession about the possible dangers of so-called lipid metabolism disorders, and thereby establishing itself as an independent contact in the interdisciplinary cooperation between doctors from different disciplines, pharmacists and their partners in the health sector.

A lipid metabolism disorder is shown by increased LDL cholesterol, lipoprotein (a) and triglyceride levels. The target values ​​of the European guidelines are indicative for classification. These target values ​​are exceeded by a large part of the population. Due to the scientific sources, the DGFF (Lipid-Liga) assesses their permanent exceedance as requiring therapy.

target

The declared goal of the DGFF (Lipid League) is, according to its own statements, "health education through the implementation and communication of established knowledge in the field of prevention, diagnosis and therapy of disorders of lipid metabolism and atherosclerosis". The DGFF (Lipid League) wants to be the independent contact for all affected groups.

history

The company was founded in 1988. Its objectives are based on the National Cholesterol Education Program (NCEP, National Cholesterol Education Program ) founded in the USA in 1985 . The basis for the work of both organizations is the scientific knowledge that LDL cholesterol, lipoprotein (a) and triglyceride levels are a major cause of arteriosclerosis and heart attacks (see cholesterol and CHD diseases ). Since it was founded, she has been campaigning for targeted and individually tailored therapy. Lifestyle changes with a fat-modified diet, regular exercise and not smoking are the basic therapy in all cases. Additional therapeutic measures are recommended for particularly severe forms of lipid metabolism disorders. The DGFF (Lipid League) is based on the guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the target values ​​for the lipid metabolism parameters.

financing

The work of the DGFF (Lipid-Liga) is financed by membership fees and sponsors, who are manufacturers of pharmaceuticals and medical-technical devices. The company's statutes exclude the sponsors from influencing the work of the organization.

Public relations and advanced training for doctors

Day of cholesterol

One of the most public events of the DGFF (Lipid League) is the "Day of Cholesterol", which has been held annually since 2003 and is carried out in conjunction with doctors' practices, clinics and pharmacies. While the pharmaceutical company Hexal (manufacturer of the cholesterol lowering drug SimvaHEXAL ) appeared as sponsor at the first such event , numerous well-known manufacturers of pharmaceuticals and lipoprotein apheresis technology are among the sponsors today.

Parents' guide and children's guidelines

The DGFF supports a nationwide self-help initiative for parents whose children are affected by inherited lipid metabolism disorders (familial hypercholesterolemia). In addition, early diagnosis should be supported in order to prevent atherosclerosis diseases as early as adolescence.

The guide values ​​for children are based on the guideline of the working group for pediatric metabolic disorders in the German Society for Pediatrics and Adolescent Medicine

If the child's total cholesterol value is “too high” (above 200 mg / dl), the doctor should decide whether therapy is necessary based on a determination of the HDL, LDL and triglyceride values.

Certain statins are currently approved for use in children aged 8 and 10 years and over. According to the authors, individual scientific studies for various statins (simvastatin, pravastatin) show that cholesterol levels in children can be "safely and effectively lowered". The former chairman of the Lipid League (DGFF), Achim Weizel, campaigned for statins to be approved for the treatment of children with familial hypercholesterolemia .

Press work and publications

In addition, the DGFF (Lipid League) regularly issues press releases and statements. In these, studies and current publications on the topic in terms of the cholesterol-CHD hypothesis are commented, interpreted and put into perspective.

The publication Lipid-Report published by the company was discontinued in 2012. The DGFF (Lipid-Liga) publishes a series of patient guides on the subjects of "lipid metabolism disorders", "elevated triglycerides", "lipoprotein (a)" and "lipoprotein apheresis".

Advanced training for doctors

To educate the medical profession, the DGFF (Lipid League) regularly organizes advanced training events and symposia, the organization of which is financially supported by sponsors. The sponsors have no influence on the form and content.

Political lobbying and criticism

In addition to educating the general public and doctors, the DGFF (Lipid League) also conducts traditional political lobbying for the early detection and adequate treatment of disorders of lipid metabolism.

The financial support from manufacturers of pharmaceuticals and medical technology devices is disclosed on the DGFF (Lipid League) website and in the programs of symposia.

See also

swell

  1. a b Željko Reiner, Alberico L. Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen: ESC / EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) . In: European Heart Journal . tape 32 , no. 14 , July 1, 2011, ISSN  0195-668X , p. 1769–1818 , doi : 10.1093 / eurheartj / ehr158 (English, oup.com [accessed on May 15, 2018]).
  2. ^ WP Castelli: Epidemiology of coronary heart disease: The Framingham study . In: The American Journal of Medicine . tape 76 , no. 2 , February 1984, ISSN  0002-9343 , pp. 4–12 , doi : 10.1016 / 0002-9343 (84) 90952-5 (English, elsevier.com [accessed on May 15, 2018]).
  3. S2k guidelines for the diagnosis and treatment of hyperlipidemia in children and adolescents. (PDF) Working Group for Pediatric Metabolic Disorders (APS) of the German Society for Pediatric and Adolescent Medicine eV (DGKJ), September 30, 2015, accessed on May 15, 2018 .

Web links